Roche Reports Results of Tecentriq in P-III IMpower010 Study for Patients with Early Lung Cancer

 Roche Reports Results of Tecentriq in P-III IMpower010 Study for Patients with Early Lung Cancer

Roche Collaborates with Atea Pharmaceuticals to Develop AT-527 for COVID-19

Shots:

  • The P-III IMpower010 study involves assessing Tecentriq vs BSC, in 1,005 participants in a ratio (1:1) with stage IB-IIIA NSCLC, following surgical resection and up to 4 cycles of adjuvant CT
  • The study met its 1EPs showed improvement in DFS in PD-L1+ stage II-IIIA populations and ITT stage IB-IIIA populations NSCLC. The 2EP’s include OS in the overall study population, ITT Stage IB-IIIA NSCLC
  • The findings will be submitted to US FDA and EUA and presented at an upcoming medical meeting. Tecentriq is approved in the US, EU, and other countries, either alone or in combination with targeted therapies and/or CT in multiple cancer indications

Click here ­to­ read full press release/ article | Ref: Roche | Image: Krauthammer

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post